BofA/Merrill Lynch Upgrades Biogen (BIIB) to Buy Following Positive Oral BG-12 Data
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $214.35 -3.25%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
An analyst at BofA/Merrill Lynch upgraded shares of Biogen (NASDAQ: BIIB) from Neutral to Buy Tuesday morning.
The upgrade follows news Monday that Biogen's Phase 3 trial for Oral BG-12 met the primary end and all secondary endpoints. Biogen shares rallied more than 7 percent following the study results.
Shares of Biogen are continuing higher this morning, now up 0.15 percent to $78.67.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
The upgrade follows news Monday that Biogen's Phase 3 trial for Oral BG-12 met the primary end and all secondary endpoints. Biogen shares rallied more than 7 percent following the study results.
Shares of Biogen are continuing higher this morning, now up 0.15 percent to $78.67.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
- Freedom Broker Upgrades Walmart (WMT) to Buy
- JPMorgan Upgrades Nokian Renkaat Oyj (TYRES:FH) (NKRKY) to Neutral
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
